Mutant BRAF drives melanoma tumor proliferation through activation of the mitogen activated kinase pathway (MAP) pathway, and resistance to BRAF inhibitors has been described in both MAP kinase-dependent and -independent pathways [25-27]. The gene discussed is BRAF; the disease is melanoma.